Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanwa Kagaku Kenkyusho Co., Ltd.

Latest From Sanwa Kagaku Kenkyusho Co., Ltd.

Amneal Kicks Off China Business With First Approval

Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.

Approvals China

Amneal Submits Modest Guidance Raise Following Strong Second Quarter

Amneal now expects an additional $50m in net revenue this year, revising its revenue expectations up to between $2.3bn and $2.4bn following a successful second quarter.

Sales & Earnings Generic Drugs

Amneal Goes After ProAir, Lumigan And Diprivan With Latest Filings

With a continuing focus on complex generics, Amneal has revealed a trio of US filings targeting ProAir, Lumigan and Diprivan.

Generic Drugs Strategy

FDA Demands More Information For Amneal Parkinson’s Disease Drug

Amneal says it will work closely with the FDA after seeing its application for the company’s IPX203 cardbidopa/levodopa extended-release turned down for approval by the agency.

Complete Response Letters Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Distributors
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Nutraceuticals
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Digital Imaging
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products